Management of pharmacovigilance during the COVID‐19 pandemic crisis by the safety department of an academic sponsor: Lessons learnt and challenges from the EU DisCoVeRy clinical trial
Noémie Mercier,Drifa Belhadi,Aline DeChanet,Christelle Delmas,Juliette Saillard,Marina Dumousseaux,Claire Fougerou‐Leurent,Assia Ferrane,Charles Burdet,Hélène Espérou,Florence Ader,Maya Hites,Nathan Peiffer‐Smadja,Julien Poissy,Claire Andrejak,José Artur Paiva,Evelina Tacconelli,Thérèse Staub,Richard Greil,Dominique Costagliola,France Mentre,Yazdan Yazdanpanah,Alpha Diallo,Séverine Gibowski,Christelle Paul,Joséphine Balssa,Elise Landry,Anaïs Le‐Goff,Solange Lancrey‐Javal,Lea Levoyer,Laurence Moachon,Vida Terzic,Mélanie Figarella,Nicolas Pittoni‐Minvielle,Anaïs Boston,Joe Miantezila‐Basilua,Pauline Ginoux,Blandine Gautier,Adele Wegang‐Nzeufo,Alain Caro,Alexandra De Lemos,Alexandra Seux,Alice Verdier,Ambre Champougny,Anne Sophie Martineau,Anne‐Lise Varnier,Aude Le Breton,Audrey Langlois,Axel Duquenoy,Beatrice Mizejewski,Benlakhryfa Assia,Bercelin Maniangou Zonzeka,Boudjoghra Nour El Houda,Brigitte Mugnier,Brigitte Risse,Camille Chevalier,Camille Harpon,Camille Jourdan,Caroline Dubois‐Gache,Celina Pruvost,Charlotte Cameli,Cherifi Asma,Chloe Bureau,Christelle Back‐Laufenburger,Christelle Lucas,Christina Schiano,Christine Pintaric,Coline Perrier,Collette Camille,David Simo,Dominique Lagarde,Edit Faillet,Elina Haerrel,Elodie Donet,Eric Marquis,Euma Fortes Lopes,Fabrice Bouhet,Florence Le Cerf,Gabriel Huguenin,Gerome Quention,Hend Madiot,Isabelle Calmont,Isabelle Gaudin,Isabelle Pacaud,Issraa Osman,Jean‐Loup Devassine,Jeremy Tobia,Justine Rousseaux,Leslie Reyrolle,Lorrie Lafuente,Lydie Antoine,Lyna Gouichiche,Malek Ait Djoudi,Manon Pelkowski,Marcellin Bellonet,Marianne Maillet,Marie Diesel,Marie Granjon,Marie Laure Stupien,Marie‐Jose Aroulanda,Marie‐Jose Ngo Um Tegue,Marielle Simon,Marine Bou,Marine Douillet,Marion Ghidi,Maxence Passageon,Melanie Grubner,Morgane Heberle,Murielle Mejane,Pietro Todessayi,Rachida Yatimi,Robin Pinilla,Sabine Camara,Sandra Marchionni,Sandrine Vautrat,Shervin Fonooni,Solange Trehoux,Sophie Tallon,Stephanie Flasquin,Stephanie Lejeune,Stuart Byrom,Sylvie Grandmange,Traikia Chaima,Valerie Opderbeck,Veronique Pelonde Perimee,Victoria Mouanga,Volanantenaina Fanomezantsoa,Nassera Aouali,Alexandra Keusching,Brigitta Elsasser,Martha Colban,Ruben E. Keane,Radka Troníčková,Katerina Nerušilová,Agnieszka Wiesner,Irene Garcia,Soizic Le Mestre,the DisCoVeRy Safety Working group,Dr Pochesci Alessia,Dr David Grimaldi,Dr Filipa Luz
DOI: https://doi.org/10.1002/prp2.1072
2023-06-03
Abstract:Safety and communication data circuit. The current COVID‐19 pandemic was an exceptional health situation, including for drug use. As there was no known effective drug for COVID‐19 at the beginning of the pandemic, different drug candidates were proposed. In this article, we present the challenges for an academic Safety Department to manage the global safety of a European trial during the pandemic. The National Institute for Health and Medical Research (Inserm) conducted a European multicenter, open‐label, randomized, controlled trial involving three repurposed and one‐in development drugs (lopinavir/ritonavir, IFN‐β1a, hydroxychloroquine, and remdesivir) in adults hospitalized with COVID‐19. From 25 March 2020 to 29 May 2020, the Inserm Safety Department had to manage 585 Serious Adverse Events (SAEs) initial notification and 396 follow‐up reports. The Inserm Safety Department's staff was mobilized to manage these SAEs and to report Expedited safety reports to the competent authorities within the legal timeframes. More than 500 queries were sent to the investigators due to a lack of or incoherent information on SAE forms. At the same time, the investigators were overwhelmed by the management of patients suffering from COVID‐19 infection. These particular conditions of missing data and lack of accurate description of adverse events made evaluation of the SAEs very difficult, particularly the assessment of the causal role of each investigational medicinal product. In parallel, working difficulties were accentuated by the national lockdown, frequent IT tool dysfunctions, delayed implementation of monitoring and the absence of automatic alerts for SAE form modification. Although COVID‐19 is a confounding factor per se, the delay in and quality of SAE form completion and the real‐time medical analysis by the Inserm Safety Department were major issues in the quick identification of potential safety signals. To conduct a high‐quality clinical trial and ensure patient safety, all stakeholders must take their roles and responsibilities.
pharmacology & pharmacy